Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Selection and characterization of a human ovarian cancer cell line resistant to auranofin.

Landini I, Lapucci A, Pratesi A, Massai L, Napoli C, Perrone G, Pinzani P, Messori L, Mini E, Nobili S.

Oncotarget. 2017 Oct 9;8(56):96062-96078. doi: 10.18632/oncotarget.21708. eCollection 2017 Nov 10.

2.

MicroRNA-31 Regulates Chemosensitivity in Malignant Pleural Mesothelioma.

Moody HL, Lind MJ, Maher SG.

Mol Ther Nucleic Acids. 2017 Sep 15;8:317-329. doi: 10.1016/j.omtn.2017.07.001. Epub 2017 Jul 8.

3.

Simultaneous overactivation of Wnt/β-catenin and TGFβ signalling by miR-128-3p confers chemoresistance-associated metastasis in NSCLC.

Cai J, Fang L, Huang Y, Li R, Xu X, Hu Z, Zhang L, Yang Y, Zhu X, Zhang H, Wu J, Huang Y, Li J, Zeng M, Song E, He Y, Zhang L, Li M.

Nat Commun. 2017 Jun 19;8:15870. doi: 10.1038/ncomms15870.

4.

Magnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approach.

Román DA, Pizarro I, Rivera L, Ávila J, Cortés P.

JRSM Open. 2016 Oct 4;7(10):2054270416660932. eCollection 2016 Oct.

5.

Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.

Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J.

BMC Cancer. 2016 Feb 23;16:140. doi: 10.1186/s12885-016-2182-8.

6.

Role of copper transporters in platinum resistance.

Kilari D, Guancial E, Kim ES.

World J Clin Oncol. 2016 Feb 10;7(1):106-13. doi: 10.5306/wjco.v7.i1.106. Review.

7.

Genetic variants in ABCG1 are associated with survival of nonsmall-cell lung cancer patients.

Wang Y, Liu H, Ready NE, Su L, Wei Y, Christiani DC, Wei Q.

Int J Cancer. 2016 Jun 1;138(11):2592-601. doi: 10.1002/ijc.29991. Epub 2016 Jan 30.

8.

Subunit composition of VRAC channels determines substrate specificity and cellular resistance to Pt-based anti-cancer drugs.

Planells-Cases R, Lutter D, Guyader C, Gerhards NM, Ullrich F, Elger DA, Kucukosmanoglu A, Xu G, Voss FK, Reincke SM, Stauber T, Blomen VA, Vis DJ, Wessels LF, Brummelkamp TR, Borst P, Rottenberg S, Jentsch TJ.

EMBO J. 2015 Dec 14;34(24):2993-3008. doi: 10.15252/embj.201592409. Epub 2015 Nov 3.

9.

Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer.

Naka A, Takeda R, Shintani M, Ogane N, Kameda Y, Aoyama T, Yoshikawa T, Kamoshida S.

Am J Cancer Res. 2015 Jun 15;5(7):2285-93. eCollection 2015.

10.

Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer.

Takeda R, Naka A, Ogane N, Kameda Y, Kawachi K, Shimizu S, Kamoshida S.

Breast Cancer (Auckl). 2015 Aug 4;9:49-57. doi: 10.4137/BCBCR.S27534. eCollection 2015.

11.

Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A, Cinatl J Jr.

Transl Oncol. 2015 Jun;8(3):210-6. doi: 10.1016/j.tranon.2015.04.002.

12.

DNA repair mechanisms in cancer development and therapy.

Torgovnick A, Schumacher B.

Front Genet. 2015 Apr 23;6:157. doi: 10.3389/fgene.2015.00157. eCollection 2015.

13.

Thyroid hormone and P-glycoprotein in tumor cells.

Davis PJ, Incerpi S, Lin HY, Tang HY, Sudha T, Mousa SA.

Biomed Res Int. 2015;2015:168427. doi: 10.1155/2015/168427. Epub 2015 Mar 19. Review.

14.

REV3L, a promising target in regulating the chemosensitivity of cervical cancer cells.

Yang L, Shi T, Liu F, Ren C, Wang Z, Li Y, Tu X, Yang G, Cheng X.

PLoS One. 2015 Mar 17;10(3):e0120334. doi: 10.1371/journal.pone.0120334. eCollection 2015.

15.

2,3,7,8-Tetrachlorodibenzo-p-dioxin induced cell-specific drug transporters with acquired cisplatin resistance in cisplatin sensitive cancer cells.

Gotovdorj T, Lee E, Lim Y, Cha EJ, Kwon D, Hong E, Kim Y, Oh MY.

J Korean Med Sci. 2014 Sep;29(9):1188-98. doi: 10.3346/jkms.2014.29.9.1188. Epub 2014 Sep 2.

16.

High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy.

Tashiro A, Tatsumi S, Takeda R, Naka A, Matsuoka H, Hashimoto Y, Hatta K, Maeda K, Kamoshida S.

Am J Cancer Res. 2014 Sep 6;4(5):528-36. eCollection 2014.

17.

Glioblastoma development in mouse brain: general reduction of OCTs and mislocalization of OCT3 transporter and subsequent uptake of ASP+ substrate to the nuclei.

Kucheryavykh LY, Rolón-Reyes K, Kucheryavykh YV, Skatchkov S, Eaton MJ, Sanabria P, Wessinger WD, Inyushin M.

J Neurosci Neuroeng. 2014 Feb;3(1):3-9.

18.

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.

Watkins JA, Irshad S, Grigoriadis A, Tutt AN.

Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670. Review.

19.

Downregulation of Ras association domain family member 6 (RASSF6) underlies the treatment resistance of highly metastatic nasopharyngeal carcinoma cells.

Liang YY, Chen MY, Hua YJ, Chen S, Zheng LS, Cao X, Peng LX, Xie P, Huang BJ, Sun R, Wang L, Xiang YQ, Guo X, Qian CN.

PLoS One. 2014 Jul 16;9(7):e100843. doi: 10.1371/journal.pone.0100843. eCollection 2014.

20.

Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy.

Tatsumi S, Matsuoka H, Hashimoto Y, Hatta K, Maeda K, Kamoshida S.

Int J Clin Exp Pathol. 2013 Dec 9;7(1):204-12. eCollection 2014.

Supplemental Content

Support Center